OTC:AKBLF

ALK-Abelló A/S (AKBLF) Stock Price, News & Analysis

$22.45
0.00 (0.00%)
(As of 05/17/2024 ET)
Today's Range
$22.45
$22.45
50-Day Range
$17.90
$22.45
52-Week Range
$8.20
$22.45
Volume
N/A
Average Volume
683 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKBLF stock logo

About ALK-Abelló A/S Stock (OTC:AKBLF)

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

AKBLF Stock Price History

AKBLF Stock News Headlines

ALK Abello: ALK upgrades its full-year revenue outlook
Three-month interim report (Q1) 2024 (unaudited)
ALK upgrades its full-year revenue outlook
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
Release date of annual report 2023 for ALK and webcast
ALK-Abello B (0OIR)
ALK – Financial calendar for the 2024 financial year
ALK Abello: ALK expands partnership with Torii in Japan
ALK expands partnership with Torii in Japan
Nine-month interim report (Q3) 2023
Alk-Abello A/S Class B ALK B
See More Headlines
Receive AKBLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALK-Abelló A/S and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,824
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Claus Steensen Solje (Age 52)
    Executive VP, CFO & Member of Management Board
    Comp: $2.03M
  • Mr. Søren Daniel Niegel (Age 53)
    Executive VP of Commercial Operations & Member of Management Board
    Comp: $766.2k
  • Dr. Henriette Mersebach (Age 53)
    Executive VP Research & Development & Member of Management Board
    Comp: $886.3k
  • Ms. Katja Barnkob Thalund (Age 55)
    Project Director of Global CMC Development & Employee-elected Director
    Comp: $50.34k
  • Mr. Peter Halling (Age 47)
    President & CEO
  • Mr. Per Plotnikof
    VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
  • Prof. Hendrik Kees Kam Nolte M.D.
    Ph.D., Senior Vice President of Research & Development - North America and International Markets
  • Mr. Christian G. Houghton
    Head of Product Supply

AKBLF Stock Analysis - Frequently Asked Questions

Should I buy or sell ALK-Abelló A/S stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALK-Abelló A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBLF shares.
View AKBLF analyst ratings
or view top-rated stocks.

How have AKBLF shares performed in 2024?

ALK-Abelló A/S's stock was trading at $13.25 at the beginning of the year. Since then, AKBLF shares have increased by 69.4% and is now trading at $22.45.
View the best growth stocks for 2024 here
.

How do I buy shares of ALK-Abelló A/S?

Shares of AKBLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTC:AKBLF) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners